Endometriosis is associated with nociceptive pain, as well as peripheral and central sensitization. Evidence-based treatment suggestions for controlling endometriosis should be based on the convergence of the best scientific evidence, …
Endometriosis is a chronic estrogen-dependent inflammatory disease that impairs fertility and quality of life. Dienogest, the current standard therapy, provides symptom relief but does not correct immune imbalance or prevent …
To evaluate the effects of letrozole alone and in combination with a gonadotropin-releasing hormone agonist on inflammatory cytokines, folliculogenesis, and hormonal profiles in a rat model of surgically induced peritoneal …
Endometriosis (EMT) is an incurable and painful chronic illness that affects approximately 10% of people assigned female at birth worldwide. Currently, EMT takes on average 5-7 years to diagnose after …
This study evaluates the synergistic therapeutic effect of metformin (MET) combined with medroxyprogesterone acetate (MPA) on endometriosis (EM) and investigates the involvement of the steroid receptor coactivator-1 (SRC-1) and mitogen-inducible …
The pathogenesis and progression of endometriosis may involve a complex combination of multiple factors, including chronic inflammation and oxidative stress. Hormonal therapy, the current standard for pharmacotherapy in endometriosis, causes …
Oxidative stress has emerged as a key factor regulating female fertility, reproductive aging, and the development of various gynecologic and pregnancy-associated diseases. While physiological concentrations of reactive oxygen species play …
Arteriovenous malformations (AVMs) are vascular anomalies defined by direct communications between arteries and veins with bypassing of the capillary network. Such lesions may be congenital or acquired. In the uterus, …
Endometriosis is a complex, estrogen-dependent disease with limited effective treatments that often focus on symptom management rather than addressing the underlying pathology. Current therapies, such as progestins and GnRH agonists, …
Elagolix sodium (ELS), a non-peptide oral gonadotropin-releasing hormone receptor (GnRH) antagonist approved for the treatment of endometriosis-associated pain, displays atypical gelation in aqueous environments along with challenging physical properties such …